IMCR Stock Analysis: Buy, Sell, or Hold?
IMCR - Immunocore Holdings plc American Depositary Shares
$31.94
-1.11 (-3.34%)
▼
5d:
-8.89%
30d:
-5.46%
90d:
-3.49%
HOLD
MODERATE Confidence
Last Updated: February 3, 2026
Earnings: Feb 25, 2026
21d
Get Alerted When IMCR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: IMCR shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: IMCR shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: IMCR is currently trading at $31.93, which is considered oversold relative to its 30-day fair value range of $32.58 to $34.82.
Technical Outlook: Technically, IMCR is showing sideways momentum. The price is currently testing key support at $31.68. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.3% recently.
Market Sentiment: IMCR has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $66.36 (+100.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, IMCR is showing sideways momentum. The price is currently testing key support at $31.68. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.3% recently.
Market Sentiment: IMCR has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $66.36 (+100.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$32.58 -
$34.82
Company Quality Score
53/100
(HOLD)
Options IV Signal
50th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
56.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 50th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.3%)
- BULLISH: Trading 100.8% below Wall St target ($66.36)
- CAUTION: 5-day price weakness (-8.9%) - monitor closely
Fair Price Analysis
30-Day Fair Range
$32.58 -
$34.82
Current vs Fair Value
OVERSOLD
Expected Move (7 Days)
±$2.24
(7.0%)
Support & Resistance Levels
Support Level
$31.68
Resistance Level
$35.95
Current Trend
Sideways
Fundamental Context
Forward P/E (Next Year Est.)
-39.41
Wall Street Target
$66.36
(+100.8%)
Revenue Growth (YoY)
29.2%
Earnings Growth (YoY)
822.0%
Profit Margin
-7.7%
Last updated: February 03, 2026 2:02 PM ET
Data refreshes hourly during market hours. Next update: 3:02 PM
Data refreshes hourly during market hours. Next update: 3:02 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IMCR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
David M Berman
SELL
200 shares
2025-09-15
David M Berman
SELL
22532 shares
2025-09-12
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 67 BUY |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1036 | 58 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$117 | 61 BUY |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$140 | 50 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 51 HOLD |
